Диссертация (1141371), страница 22
Текст из файла (страница 22)
Hewlett, L. Survey of naloxone legal status in opioid overdose prevention / Hewlett, L.and Wermeling, D. // J Opioid Mgmt 2013, 9: 369–377.82. Hong J. Allergy to ophthalmic preservatives / Hong J, Bielory L. // Curr Opin AllergyClin Immunol. 2009; 9(5):447-453.83. Human factors engineering—Design of medical devices, ANSI/AAMI HE75, 2009/(R)2013.84. ICH Harmonised Tripartite Guideline: Pharmaceutical Development Q8; Step 4 version,November 2005.85.
Jones, C. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse –related emergency department visits and drug-related deaths / Jones, C., Paulozzi, L.and Mack, K. – United States, 2010. CDC MMWR 63(40): 881–885.86.Kalkotwar, RS. EVALUATION AND QUALITY CONTROL OF NASAL SPRAY/Patil Vidya Bankar, Kalkotwar RS, Patel Ankita, Tathe Swati, Jadhav VB // Journal ofDrug Delivery & Therapeutics; 2012, 2(4), 1-4.87. Kelly, A.
Randomised trial of intranasal versus intramuscular naloxone in prehospitaltreatment for suspected opioid overdose / Kelly, A., Kerr, D., Dietze, P., Patrick, I.,Walker, T. and Koutsogiannis, Z. // Med J Aust 2005, 182: 24–27.88. Kerr, D. Intranasal naloxone for the treatment of suspected heroin overdose / Kerr, D.,Dietze, P.
and Kelly, A. // Addiction 2008, 103: 379–386.89. Kerr, D. Randomized controlled trial comparing the effectiveness and safety ofintranasal and intramuscular naloxone for the treatment of suspected heroin overdose /Kerr, D., Kelly, A., Dietze, P., Jolley, D. and Barger, B. // Addiction 2009, 104: 2067–2074.14190. Kibbe A.H., (Ed), Handbook of pharmaceutical excipients, 3rd Edition, Am. Pharm.Asso., 392-398, 442-444 (2000).91. Knoester, P.D.
Pharmacokinetics and pharmacodynamics of midazolam administered asa concentrated intranasal spray. A study in healthy volunteers / Knoester, P.D., Jonker,D.M., van der Hoeven, R.T.M. et al. // Br. J. Clin. Pharmacol. 2002, 53, 501–507.92. Law S.L., et al, ‘Preparation of desmopressin containing liposomes for intranasaldelivery’, J. Control. Rel., 70: 375-382 (2001).93. Leary, A.C. Pharmacokinetics and pharmacodynamics of intranasal insulin spray(Nasulin) administered to healthy male volunteers: infuence of the nasal cycle / LearyAC, Dowling M, Cussen K, O'Brien J, Stote RM.
// J Diabetes Sci Technol. 2008, 2(6):1054-60.94. Lenton S.R. A trial of naloxone for peer administration has merit, but will the lawyerslet it happen / Lenton S.R., Hargreaves K.M. // Drug and Alcohol Review. – 2000. –Vol. 19. – Р. 365-369.95. Lim D., Melucci J., Rizer M.K., Prier B.E., Weber R.J. Detection of adverse drugevents using an electronic trigger tool // Am J Health Syst Pharm. 2016 Sep 1;73(17Suppl 4):S112-20. doi: 10.2146/ajhp150481.96. Loimer, N. Nasal administration of naloxone is as effective as the intravenous route inopiate addicts / Loimer, N., Hofmann, P., Chaudhry, H.R. // Int. J.
Addict. 1994, 29,819–827.97.Longest P. W., Hindle M. Small Airway Absorption and Microdosimetryof Inhaled Corticosteroid Particles afterDeposition//PharmRes. 2017Oct;34(10):2049-2065. doi: 10.1007/s11095-017-2210-7.Suman, J.D. Validity of invitro tests on aqueous spray pumps as surrogates for nasal deposition / Suman JD,Laube BL, Lin TC, Brouet G, Dalby R. // Pharm Res. 2002;19(1):1-6.98.
Lyon, A., McIntosh, N., 1985. Rectal aminophylline in the management of apnoea ofprematurity. Arch. Dis. Child. 60, 38–41. MHRA, 2011. Buccal Midazolam(Buccolam): New Authorised Medicine forPaediatric Use—care Needed whenTransferringfromUnlicensedFormulations(accessedonhttp://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON131931.12.2.14.).14299.Madah-Amiri D., Clausen T., Lobmaier P. Rapid widespread distribution ofintranasal naloxone for overdose prevention. // Drug Alcohol Depend. 2017 Apr1;173:17-23. doi: 10.1016/j.drugalcdep.2016.12.013.100.
Marx D and Birkhoff M (2011). Multi-Dose Container for Nasal and OphthalmicDrugs: A Preservative Free Future, Drug Development - A Case Study Based Insightinto Modern Strategies, Dr. Chris Rundfeldt (Ed.), ISBN: 978-953-307-257-9, InTech,DOI: 10.5772/27767.101. Marx D and Birkhoff M. Will the future be preservative free? Manufacturing ChemistPharma,published17thMay2013,accessathttp://www.manufacturingchemist.com/technical/article_page/Will_the_future_be_preservativefree/88155102.
Marx D, Leitz M, Fagot C. Do We Need New Devices for Intranasal Vaccination? DrugDevelopment & Delivery. 2011, 11 (3): 54-59.103. McDonald R., Lorch U., Woodward J., Bosse B., Dooner H., Mundin G., SmithK., Strang J. Pharmacokinetics of concentrated naloxone nasal spray for opioidoverdose reversal: Phase I healthy volunteer study // Addiction. 2017 Nov 16.
doi:10.1111/add.14033.104. Medizinproduke fur benzalkoniumchlorid-haltige Arzneimittel zur Anwendung in derNase, A 37489/38186/03 Bonn, Dezember 2003.105. Merkus, P. Direct access of drugs to the human brain after intranasal drugadministration? / Merkus, P., Guchelaar, H.-J., Bosch, D.A., Merkus, F.W. // Neurology2003, 60, 1669–1671.106.
Merlin M.A., Ariyaprakai N., Arshad F.H. Assessment of the safety and ease of use ofthe naloxone auto-injector for the reversal of opioid overdose // Open Access EmergMed. 2015 Jun 8;7:21-4. doi: 10.2147/OAEM.S82133.107. Merlin, M.A. Intranasal naloxone delivery is an alternative to intravenous naloxone foropioid overdoses / Merlin, M.A., Saybolt, M., Kapitanyan, R., Alter, S.M., Jeges, J.,Liu, J., Calabrese, S.,Rynn, K.O., Perritt, R., Pryor 2nd, P.W. // Am. J.
Emerg. Med2010, 28, 296–303.143108. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry,Manufacturing and Controls Documentation, U.S. Department of Health and HumanServices, Food and Drug Administration, Center for Drug Evaluation and Research(CDER), Juny 2002.109. Neale, J. Naloxone—does over-antagonism matter? Evidence of iatrogenic harm afteremergency treatment of heroin/opioid overdose / Neale, J., Strang, J.
// Addiction 2015,110, 1644–1652.110. Paderni, C. Controlled delivery of naltrexone by an intraoral device: in vivo study onhuman subjects / Paderni, C., Campisi, G., Schumacher, A., Gottsche, T., Giannola,L.I., De Caro, V., Wolff, A. // Int. J. Pharm. 2013, 452, 128–134.111. Peyrière, H., Léglise, Y., Rousseau, A., Cartier, C., Gibaja, V., Galland, P.,2013.Necrosis of the intranasal structures and soft palate as a result of heroin snorting: acase series.
Subst. Abuse 34, 409–414.112. Pharmacopeia of the United State. USP 38/ NF 33. 2015.113. Rech M.A., Barbas B., Chaney W., Greenhalgh E., Turck C. When to Pick the Nose:Out-of-Hospital and Emergency Department Intranasal Administration of Medications// Ann Emerg Med. 2017 Aug;70(2):203-211. doi: 10.1016/ aas.12898.114.
Robertson, T. Intranasal naloxone is a viable alternative to intravenous naloxone forprehospital narcotic overdose / Robertson, T., Hendey, G., Stroh, G. and Shalit, M. //Prehosp Emerg Care 2009, 13: 512–515.115. Robinson A., Wermeling DP. Intranasal naloxone administration for treatment of opioidoverdose // Am J Health Syst Pharm. 2014 Dec 15;71(24):2129-35. doi:10.2146/ajhp130798.116. Rosen, L.
Trends and geographic patterns in drug-poisoning death rates in the US,1999–2009 / Rosen, L., Khan, D. and Warner, M. // Am J Prev Med 2013, 45: e19–e25.117. Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence andclinicalimplications//10.1177/2042098617744161.TherAdvDrugSaf.2018Jan;9(1):63-88.doi:144118. Rando, J. Intranasal naloxone administration by police first responders is associatedwith decreased opioid overdose deaths / Rando, J., Broering, D., Olson, J.E., Marco, C.,Evans, S.B. // Am. J.
Emerg. Med. 2015, 33, 1201–1204.119. Schmidt B.L., Gear R.W., Levine J.D. Response of neuropathic trigeminal pain to thecombination of low-dose nalbuphine plus naloxone in humans // Neuroscience Letters.– 2003. – Vol. 343, № 2. – P. 144-146.120. Schwagmeier, R., Alincic, S., Striebel, H., 1998. Midazolam pharmacokineticsfollowing intravenous and buccal administration.
Br. J. Clin. Pharmacol. 46,203–206.Standring, S., 2015. Gray’s Anatomy. Elsevier Health Sciences, Amsterdam.121. Shah, N., Lathrop, S., Reichard, R. and Landen, M. (2007) Unintentional drug overdosedeath trends in New Mexico, USA, 1990–2005: combinations of heroin, cocaine,prescription opioids and alcohol. Addiction 103: 126–136.122. Shcherbakova N., Tereso G., Spain J., Roose R.J.. Treatment Persistence AmongInsured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder //Ann Pharmacother.
2018 Jan 1:1060028017751913. doi: 10.1177/1060028017751913.123. Sporer, K. and Kral, A. (2007) Prescription naloxone: a novel approach to heroinoverdose prevention. Ann Emerg Med 49: 172–177.124. Stability testing of new drug substances and products Q1A, ICH harmonized tripartiteguideline, 6 February 2003.125. Strang, J., McDonald, R., Tas, B., Day, E., 2016. Clinical provision of improvised nasalnaloxone without experimental testing and without regulatory approval: imaginativeshortcutordangerousbypassofessentialsafetyprocedures?Addiction,http://dx.doi.org/10.1111/add.13209.126.
Taylor, D. Buccal midazolam for agitation on psychiatric intensive care wards / Taylor,D., Okocha, C., Paton, C., Smith, S., Connolly, A. // Int. J. Psychiatry Clin. Pract. 2008,12,309–311.127. Toblin, R. Mental illness and psychotropic use among prescription drug overdosedeaths: a medical examiner chart review / Toblin, R., Paulozzi, L., Logan, J., Hall, A.and Kaplan, J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
